A Phase 1 interventional study of PBK_M2301 (levodropropizine + Pelargonium sidoides extract) and R1_PBK_M2301 (levodropropizine) in Healthy Volunteers, sponsored by Pharmbio Korea Co., Ltd.. Recruiting at 1 site in South Korea. Open to participants aged 19 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-12.
Sponsored by Pharmbio Korea Co., Ltd. · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this Phase 1 clinical trial is to evaluate the safety and pharmacokinetic characteristics of PBK_M2301 in healthy adult volunteers. The main questions it aims to answer are:
What are the maximum concentration (Cmax) and total drug exposure (AUCt) of PBK_M2301 compared to the combination of two reference drugs?
Are there any safety concerns associated with a single oral dose of PBK_M2301?
Researchers will compare PBK_M2301 with the combination of R1_PBK_M2301 and R2_PBK_M2301 to assess differences in drug levels.
Participants will:
Receive each treatment once in a randomized sequence with a one-week washout in between
Provide blood samples at multiple time points after dosing
Undergo safety assessments including adverse event monitoring, vital signs, laboratory tests, and ECGs
This Phase 1, open-label, randomized, two-period, two-sequence crossover study will evaluate the safety and pharmacokinetic characteristics of PBK_M2301 in 32 healthy adults. PBK_M2301 contains levodropropizine 60 mg and Pelargonium sidoides extract 20 mg per tablet.
Participants will receive either a single dose of PBK_M2301 or a combination of two reference drugs (R1_PBK_M2301 and R2_PBK_M2301) in a randomized sequence, with a one-week washout between treatments. Blood samples will be collected at multiple time points up to 12 hours post-dose to determine plasma concentrations of levodropropizine using a validated LC-MS/MS method.
Primary endpoints are Cmax and AUCt, with secondary endpoints including AUC∞, Tmax, t1/2, CL/F, and Vz/F. Safety will be assessed by monitoring adverse events, vital signs, laboratory tests, and ECGs throughout the study.
Pharmbio Korea Co., Ltd. is the lead sponsor of 10 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects who meet all of the following criteria may be included in the study:
(BMI) between 18 and 30 kg/m² (inclusive) at screening (BMI = weight (kg) / height (m)²):
Agrees to use medically acceptable * (excluding hormonal contraceptives) from the first administration of the investigational product until 1 week after the last administration, to prevent pregnancy in themselves or their spouse/partner, and agrees not to donate sperm or ova during this period.
2 Exclusion Criteria
Subjects who meet any of the following criteria will be excluded from the study:
Within 1 month prior to the first administration:
For female subjects: average alcohol consumption > 14 units/week.
(1 unit = 50 mL soju, 250 mL beer, or 30 mL whisky)
Presence of the following conditions:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this arm will receive a single oral dose of R1\_PBK\_M2301 (levodropropizine 60 mg) plus R2\_PBK\_M2301 (Pelargonium sidoides extract 20 mg) in Period 1, followed by a one-week washout, and then a single oral dose of PBK\_M2301 (levodropropizine 60 mg + Pelargonium sidoides extract 20 mg) in Period 2. All doses will be administered after at least 10 hours of fasting, with 150 mL of water at room temperature.
Drug: PBK_M2301 (levodropropizine + Pelargonium sidoides extract) · Drug: R1_PBK_M2301 (levodropropizine) · Drug: R2_PBK_M2301 (Pelargonium sidoides extract)
Participants in this arm will receive a single oral dose of PBK\_M2301 (levodropropizine 60 mg + Pelargonium sidoides extract 20 mg) in Period 1, followed by a one-week washout, and then a single oral dose of R1\_PBK\_M2301 (levodropropizine 60 mg) plus R2\_PBK\_M2301 (Pelargonium sidoides extract 20 mg) in Period 2. All doses will be administered after at least 10 hours of fasting, with 150 mL of water at room temperature.
Drug: PBK_M2301 (levodropropizine + Pelargonium sidoides extract) · Drug: R1_PBK_M2301 (levodropropizine) · Drug: R2_PBK_M2301 (Pelargonium sidoides extract)
A single oral tablet containing levodropropizine 60 mg and Pelargonium sidoides extract (11% ethanol dried extract, 5.5\~6.6→1) 20 mg. Administered after at least 10 hours of fasting with 150 mL of water at room temperature.
Also known as: PBK_M2301
A single oral tablet containing levodropropizine 60 mg. Administered after at least 10 hours of fasting with 150 mL of water at room temperature.
Also known as: R1_PBK_M2301
A single oral tablet containing Pelargonium sidoides extract (11% ethanol dried extract, 5.5\~6.6→1) 20 mg. Administered after at least 10 hours of fasting with 150 mL of water at room temperature.
Also known as: R2_PBK_M2301
Maximum plasma concentration (Cmax) of Levodropropizine
Cmax will be determined from plasma concentration-time data following single and multiple oral doses of PBK\_M2301, administered alone and in combination with R1\_PBK\_M2301 or R2\_PBK\_M2301.
Time frame: Pre-dose (0 hours) to 12 hours post-dose (depending on dosing regimen)
Area under the plasma concentration-time curve from time 0 to the last quantifiable concentration (AUCt) of Levodropropizine
AUCt will be calculated using the linear trapezoidal method based on plasma concentration-time data, in accordance with "Regulations on Bioequivalence Tests" (Article 17).
Time frame: Pre-dose (0 hours) to 12 hours post-dose (depending on dosing regimen)
Area under the plasma concentration-time curve extrapolated to infinity (AUC∞) of Levodropropizine
AUC∞ will be derived as the sum of AUCt and the extrapolated terminal area (Ct/λZ) using noncompartmental analysis, following single and multiple oral doses of Levodropropizine, administered alone and in combination with R1\_PBK\_M2301 or R2\_PBK\_M2301.
Time frame: Pre-dose (0 hours) to last quantifiable concentration plus extrapolated terminal phase (up to 12 hours post-dose)
Ratio of AUCt to AUC∞ of Levodropropizine
The percentage of AUCt relative to AUC∞ will be calculated for each participant to assess the proportion of the observed exposure, following single and multiple oral doses of Levodropropizine, administered alone and in combination with R1\_PBK\_M2301 or R2\_PBK\_M2301.
Time frame: Pre-dose (0 hours) to last quantifiable concentration plus extrapolated terminal phase (up to 12 hours post-dose)
Time to reach maximum plasma concentration (Tmax) of Levodropropizine
Tmax will be recorded as the actual observed time of maximum plasma concentration for each participant after single and multiple oral doses of Levodropropizine, administered alone and in combination with R1\_PBK\_M2301 or R2\_PBK\_M2301.
Time frame: Pre-dose (0 hours) to 12 hours post-dose
Terminal elimination half-life (t1/2) of Levodropropizine
t1/2 will be estimated from the terminal slope of the log-linear portion of the plasma concentration-time curve after single and multiple oral doses of Levodropropizine, administered alone and in combination with R1\_PBK\_M2301 or R2\_PBK\_M2301.
Time frame: From Cmax to terminal phase (up to 12 hours post-dose)
Apparent oral clearance (CL/F) of Levodropropizine
CL/F will be calculated as the ratio of dose to AUC∞ using noncompartmental methods, following single and multiple oral doses of Levodropropizine, administered alone and in combination with R1\_PBK\_M2301 or R2\_PBK\_M2301.
Time frame: From dosing to terminal phase (up to 12 hours post-dose)
Apparent volume of distribution (Vz/F) of Levodropropizine
Vz/F will be estimated using noncompartmental analysis based on plasma concentration-time data following single and multiple oral doses of Levodropropizine, administered alone and in combination with R1\_PBK\_M2301 or R2\_PBK\_M2301.
Time frame: From dosing to terminal phase (up to 12 hours post-dose)
Plan to share: No — Individual participant data (IPD) will not be shared due to internal policy and data protection regulations. The dataset is limited to a small population of healthy volunteers and is intended solely for internal analysis and regulatory submission.
No publications or documents are linked to this record.
Started Aug 2025 (actual). Primary completion is estimated for Oct 2025, 2 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dipropizine
Pharmbio Korea Co., Ltd.